Literature DB >> 26555550

Toxic epidermal necrolysis due to therapy with cyclophosphamide and mesna. A case report of a patient with seronegative rheumatoid arthritis and rheumatoid vasculitis.

A C Chowdhury1, D P Misra2, P S Patro1, V Agarwal1.   

Abstract

Rheumatoid vasculitis usually occurs on the background of seropositive rheumatoid arthritis, although in rare cases the patients can be seronegative. We report a woman with seronegative rheumatoid arthritis with rheumatoid vasculitis who developed toxic epidermal necrolysis involving most of her body surface area, while on therapy with intravenous cyclophosphamide and mesna. After withdrawal of suspected offending agents, administration of intravenous immunoglobulin, and supportive therapy, she had a favorable outcome. Such an occurrence is rare and serves to educate about a potentially life-threatening adverse event associated with a commonly used immunosuppressive agent.

Entities:  

Keywords:  Adverse drug reaction; Immunoglobulin; Immunosuppressive agents; Rheumatoid vasculitis; Seronegative rheumatoid vasculitis

Mesh:

Substances:

Year:  2016        PMID: 26555550     DOI: 10.1007/s00393-015-1632-z

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  13 in total

1.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.

Authors:  S Bastuji-Garin; N Fouchard; M Bertocchi; J C Roujeau; J Revuz; P Wolkenstein
Journal:  J Invest Dermatol       Date:  2000-08       Impact factor: 8.551

2.  Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications.

Authors:  Julie Papay; Nancy Yuen; Greg Powell; Maja Mockenhaupt; Thomas Bogenrieder
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-12-05       Impact factor: 2.890

3.  EULAR recommendations for the management of primary small and medium vessel vasculitis.

Authors:  C Mukhtyar; L Guillevin; M C Cid; B Dasgupta; K de Groot; W Gross; T Hauser; B Hellmich; D Jayne; C G M Kallenberg; P A Merkel; H Raspe; C Salvarani; D G I Scott; C Stegeman; R Watts; K Westman; J Witter; H Yazici; R Luqmani
Journal:  Ann Rheum Dis       Date:  2008-04-15       Impact factor: 19.103

Review 4.  Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options.

Authors:  Scott Worswick; Jonathan Cotliar
Journal:  Dermatol Ther       Date:  2011 Mar-Apr       Impact factor: 2.851

5.  Stevens-Johnson syndrome induced by cyclophosphamide: report of two cases.

Authors:  H Assier-Bonnet; S Aractingi; J Cadranel; J Wechsler; C Mayaud; P Saiag
Journal:  Br J Dermatol       Date:  1996-11       Impact factor: 9.302

6.  Stevens-Johnson syndrome during an immunosuppressive therapy with cyclophosphamide and prednisone.

Authors:  J U Leititis; R Burghard; E Rietschel; C H Rieger; M Brandis
Journal:  Klin Padiatr       Date:  1985 Sep-Oct       Impact factor: 1.349

Review 7.  Rheumatoid vasculitis: vanishing menace or target for new treatments?

Authors:  Christie M Bartels; Alan J Bridges
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

Review 8.  Vasculitis in rheumatoid arthritis.

Authors:  Carl Turesson; Eric L Matteson
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

9.  Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis.

Authors:  D G Scott; P A Bacon
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

10.  Pulse therapy in pemphigus: report of 11 cases.

Authors:  Nurimar Conceição Fernandes; Mariana Menezes
Journal:  An Bras Dermatol       Date:  2013 Jul-Aug       Impact factor: 1.896

View more
  1 in total

1.  Toxic epidermal necrolysis in a female with metastatic breast cancer treated with vinorelbine.

Authors:  A Bazine; M Fetohi; T Namad; J El Benaye; M A Ennouhi; T Mahfoud; M Ichou
Journal:  Ann Burns Fire Disasters       Date:  2017-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.